-transparent.png){kind=logo}
Misoprostol (SC-29333) is a synthetic prostaglandin E1 analog that has been found to be a potent inhibitor of gastric secretion in animals. Nocturnal gastric antisecretory activity of misoprostol, in tablet form, was studied in 16 adult volunteers, under basal condition. The study was a randomized, double-blind, cross-over, comparison of placebo, and three graded doses of misoprostol (50, 100, and 200 micrograms). Misoprostol exhibited a statistically significant inhibition of total acid output only at the 200 micrograms dose and this inhibition was maintained for 3 h postadministration of the drug. The antisecretory effects of misoprostol were characterized by suppression of H+ ion but not of the volume of gastric secretion. No untoward effects were noted in the volunteers. As a consequence of the gastric antisecretory effects, the present studies indicate that misoprostol is a promising therapeutic agent for the treatment of peptic ulcer.
K Akdamar, and
N Agrawal, and
A Ertan
January 1985,
Arzneimittel-Forschung,
K Akdamar, and
N Agrawal, and
A Ertan
January 1987,
Advances in prostaglandin, thromboxane, and leukotriene research,
K Akdamar, and
N Agrawal, and
A Ertan
January 1993,
Polski tygodnik lekarski (Warsaw, Poland : 1960),
K Akdamar, and
N Agrawal, and
A Ertan
January 1985,
British journal of clinical pharmacology,
K Akdamar, and
N Agrawal, and
A Ertan
October 1983,
Digestive diseases and sciences,
K Akdamar, and
N Agrawal, and
A Ertan
March 1969,
Nature,
K Akdamar, and
N Agrawal, and
A Ertan
January 1986,
Current medical research and opinion,
K Akdamar, and
N Agrawal, and
A Ertan
May 1989,
Journal of clinical pharmacology,
K Akdamar, and
N Agrawal, and
A Ertan
July 1994,
Diseases of the colon and rectum,
K Akdamar, and
N Agrawal, and
A Ertan
July 1983,
The Indian journal of medical research,
